A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children

Archives of Disease in Childhood

Volumn 98, Issue 12, 2013, Pages 998-1003

  Ferrandiz Pulido, Carla ^a   Garcia Patos, Vicente ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; IMMUNOGLOBULIN; LAMOTRIGINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PENICILLIN DERIVATIVE; PHENOBARBITAL; SULFONAMIDE; VALPROIC ACID;

CHILDHOOD DISEASE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG EXPOSURE; GENETIC SUSCEPTIBILITY; HUMAN; MORTALITY; NUTRITIONAL SUPPORT; OCCUPATIONAL THERAPY; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; PRODROMAL SYMPTOM; REVIEW; STEVENS JOHNSON SYNDROME; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE; WOUND DRESSING;

DERMATOLOGY; INTENSIVE CARE; MULTIDISCIPLINARY TEAM-CARE;

ADULT; CHILD; DIAGNOSIS, DIFFERENTIAL; EPIDERMIS; HUMANS; INCIDENCE; STEVENS-JOHNSON SYNDROME;

EID: 84888638658     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303718     Document Type: Review

References (47)

1. Stevens AM, Johnson FC. A new eruptive fever associates with stomatitis and ophthalmia; report of two cases in children. Am J Dis Child 1922;24:526-33.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61.
3. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
4. Bastuji-Garin S, Rzany B, Stern RS, et al . Clinical classi fication of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
5. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
6. Sotelo-Cruz N. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Gac Med Mex 2012;148:265-75.
7. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativ ummultiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73.
8. Goyal S, Gupta P, Ryan CM, et al. Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations. J Burn Care Res 2009;30:437-49.
9. Lam NS, Yang YH, Wang LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004;37:366-70.
10. García-Fernández D, García-Patos Briones V, Castells Rodellas A. Síndrome de Stevens/Johnson/necrólisis epidérmica tóxica. Piel 2001;16:444-57.
11. Ho JC, Ng PL, Tan SH, et al. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol 2007;24:E40-3.
12. Criado PR, Avancini J, Santi CG, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses and the immune system. Isr Med Assoc J 2012;14:577-82.
13. Lin TK, Hsu MM, Lee JY. Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome ortoxic epidermal necrolysis: report of two cases. J Formos Med Assoc 2002;101:572-6.
14. Macias ES, Pereira FA, Rietkerk W, et al. Superantigens in dermatology. J Am Acad Dermatol 2011;64:455-72.
15. Assier H, Bastujigarin S, Revuz J, et al. Erythema multiforme with mucous-membrane involvement and Stevens-Johnson Syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995;131:539-43.
16. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-24.
17. Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs. Curr Allergy Asthma Rep 2003;3:22-9.
18. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012;13:1285-306.
19. Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr 2009;21:505-10.
20. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol Int 2010;59:325-32.
21. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-22.
22. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-13.
23. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200.
24. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009;123:297-304.
25. Kunimi Y, Hirata Y, Aihara M, et al. Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan. Allergol Int 2011;60:525-32.
26. Ferrándiz-Pulido C, García-Fernández D, Domínguez-Sampedro P, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital. J Eur Acad Dermatol Venereol 2011;25:1153-9.
27. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002;25:965-72.
28. Halevy S, Ghislain PD, Mockenhaupt M, et al. EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.
29. Spies M, Sanford AP, Aili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001;108:1162-8.
30. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002;109:74-8.
31. Koh MJ, Tay YK. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol 2010;62:54-60.
32. Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008;144:232-5.
33. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439-44.
34. Prendiville JS, Hebert AA, Greenwald MJ, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-7.
35. Sheridan RL, Weber JM, Schulz JT, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20:497-500.
36. Freiman A, Borsuk D, Sasseville D. Dermatologic emergencies. CMAJ 2005;173:1317-9.
37. Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol 2012;53:165-71.
38. Mayes T, Gottschlich M, Khoury J, et al . Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008;23:547-50.
39. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
40. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007;33:452-9.
41. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005;71:398-400.
42. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.
43. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol 2011;18:e121-33.
44. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.
45. de Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteriemia in Stevens-Johnson síndrome and toxic epidermal necrolysis. Epidemiology, risk factors, and predictive value of skin cultures. Medicine 2009;89:28-36.
46. Bastuji-Garin S, Fouchard N, Berocchi M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
47. Trent JT, Kirsner RS, Romanelli P, et al . Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003;139:39-43.